Oral Contraceptive Pills and Breast Cancer Risk
Current or recent use of oral contraceptive pills increases breast cancer risk by approximately 20-30%, with a relative risk of 1.24 for combined formulations and 1.21 for progestin-only formulations, but this risk disappears within 10 years of discontinuation. 1
Magnitude of Risk by Formulation
The risk elevation varies by specific formulation:
- Combined oral contraceptives: RR 1.12-1.24 (95% CI, 1.15-1.33) for current users 1
- Progestin-only pills: RR 1.21-1.29 (95% CI, 1.17-1.25) 1, 2
- Specific high-risk formulations:
The most recent large-scale research from 2025 involving over 2 million women confirms these findings, showing ever-use of any hormonal contraceptive carries an HR of 1.24 (95% CI, 1.20-1.28) 3.
Absolute Risk Context
The absolute excess risk remains small, particularly in younger women where baseline breast cancer incidence is lowest 1:
- Ages 16-20: 8 additional cases per 100,000 users over 15 years with 5 years of use 2
- Ages 35-39: 265 additional cases per 100,000 users over 15 years with 5 years of use 2
Notably, the increased relative risk is paradoxically greatest in women under 34 years of age, precisely when the absolute incidence of breast cancer is at its lowest 1.
Critical Temporal Factors
The risk is confined to current and recent users only:
- Risk elevation present during current use and up to 5 years after discontinuation 1, 5
- Risk returns to baseline 10 years after stopping OCPs 1
- No increased risk in former users who stopped >10 years ago, regardless of duration of prior use 1
Duration and Age Considerations
Duration of use does NOT appear to correlate with increased risk 1, which is a critical distinction from other risk factors. However:
- Age at first use is the only factor consistently associated with overall increased risk 1
- Early initiation (before age 20-25) may confer higher risk, particularly for early-onset breast cancer diagnosed before age 40 6
- Among women aged ≥40 years, recent studies show small but non-significant increased risks 7, 8
Important Clinical Caveats
Family history and BRCA carrier status: Current evidence does NOT suggest that women with family history of breast cancer or BRCA1/2 mutations have a modified (amplified) risk from OCP use compared to their already elevated baseline risk 9. However, conflicting data exist for BRCA carriers specifically 10, 6, warranting individualized counseling in this population.
Tumor characteristics: The diagnosed breast cancers in OCP users tend to be more localized with less nodal spread and fewer distant metastases compared to non-users 5.
Risk-Benefit Balance
The protective effects against other cancers must be weighed against breast cancer risk:
- Decreased risk for colorectal, ovarian, and endometrial cancers in COC users 1
- Ovarian cancer risk reduced by approximately 50% 1
- These protective effects persist long-term
The overall cancer burden does not necessarily increase with OCP use when all cancer types are considered together 11.
Practical Prescribing Guidance
For women concerned about breast cancer risk:
- Emphasize the temporal nature: Risk is reversible and disappears 10 years post-discontinuation
- Quantify absolute risk: Use age-specific absolute risk numbers rather than relative risks
- Consider formulation: Levonorgestrel-containing combined pills may carry slightly lower risk than desogestrel formulations 3, 4
- Avoid in active breast cancer: OCPs are contraindicated (Category 4) in current breast cancer 9
- Caution in breast cancer history: Category 3 for past breast cancer with no evidence of disease for 5 years 9
The evidence consistently shows a modest, temporary elevation in breast cancer risk with current OCP use that must be contextualized against the very low absolute risk in younger women and the substantial benefits for contraception and protection against other malignancies.